TNFRSF9 and neoplasm: In vitro tumor reactivity was determined on day 14 of REP, the potential day of infusion and demonstrated significantly increased cytotoxicity (CD137+ fraction 62.9 ± 11.0%; unseparated 47.5 ± 12.6%; p ≤ 0.021) (Figure 4C).